With the promise of better specificity and safety, antibody-based drugs are a powerful tool for treating disease. But finding the best candidates to move through development can be time consuming and expensive. It’s not just about screening to find the highest-affinity binder, it’s also about finding the antibody that can promote the desired biological response while avoiding off-target binding and toxicity.
The iQue Screener speeds your antibody discovery programs by reducing screening time while increasing the amount and kind of data you can collect. In just a fraction of the time it takes to do a high-throughput ELISA—and using far less target protein—the iQue Screener not only provides quantitative binding information, it can also deliver data from cell-based assays that report on functions such as membrane integrity, cytokine release, and more. This comprehensive data set helps you make more informed decisions about potential leads faster, reducing discovery time, reducing discovery costs, and conserving valuable reagents.